3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Docetaxel
6
Radiotherapy
5
Filgrastim
3
Erlotinib Hydrochloride
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
entrectinib
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
cevimeline
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
entrectinib
×
CNS
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA